EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors

Zheng Jiang, Nian Yang, Jing Jin, Zongliang Zhang, Huaqing Lu, Long Xu, Yongdong Chen, Liyuan Jin, Liangxue Zhou, Hui Yang, Jun Liu, Weiwei Zhang und 2 weitere

Journal for ImmunoTherapy of Cancer · 2025-06 · 13 (6) · e011642

DOI: 10.1136/jitc-2025-011642 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 08.06.2025. Verfasst von Zheng Jiang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center, Sichuan University West China Hospital, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Interleukin-12, Oncolytic Viruses, Neoplasms, Oncolytic Virotherapy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the National Natural Sciences Foundation of China, Clinical Research Incubation Project of West China Hospital, Sichuan Provincial Science and Technology Department Key Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SKV-012 is a novel engineered oncolytic virus (containing the viral neurovirulence ICP34.5 gene transcribed by the Survivin promoter with an upstream genetic component of interleukin-12 (IL-12) driven by the cytomegalovirus promoter) that preferentially replicates in tumors and helps stimulate antitumor immune responses.

Methods

We evaluated SKV-012’s safety and efficacy in preclinical models. In a phase I trial, patients with advanced solid tumors received intratumoral injections of escalating doses of SKV-012. Primary endpoints were safety and tolerability, while secondary endpoints were antitumor response and changes in the tumor microenvironment (TME), assessed by RECIST v1.1 criteria and multiplex immunohistochemistry and single-cell transcriptome analysis.

Results

SKV-012-infected tumor cells secreted high levels of IL-12 and exhibited increased ICP34.5 expression. The combination of oncolytic herpesvirus and IL-12 was proven to reshape the TME by increasing the infiltration of immune cells, thereby significantly inducing immune cell-mediated cytolysis of tumor cells both in vitro and in animal models. Based on this, we then tested the safety, efficacy and immunogenicity of SKV-012 in patients with advanced solid cancers in a phase I clinical trial ( NCT06080984 ). No dose-limiting toxicities were observed, and adverse events were mild. Three patients achieved partial responses; one had stable disease and two had progressive disease. SKV-012 altered the TME, increasing CD8+ T cells, conventional dendritic cells, and programmed death-ligand 1 expression.

Conclusions

Intratumoral SKV-012 injections demonstrated a favorable safety profile and promising efficacy in animal models and patients with advanced cancers, thereby implicating its potential for clinical application in treatment-resistant advanced solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-12Oncolytic VirusesNeoplasmsOncolytic VirotherapyHumansAnimalsFemaleMaleMiddle AgedMiceInjections, IntralesionalAgedTumor MicroenvironmentAdultCell Line, Tumor

Stichwörter der Autor:innen

Head and Neck CancerMelanomaOncolytic virusSarcoma

Substanzen

Interleukin-12

Autor:innen und Institutionen

  • Department of Biotherapy, Cancer Center, Sichuan University West China Hospital, Chengdu, Sichuan, China.
  • State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital of Sichuan Universit…
  • Fifth People's Hospital of Ningxia Hui Autonomous Region, Shizuishan, Ningxia, China.
  • Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
  • Department of Neurosurgery, NHC Key Laboratory of Nuclear Technology Medical Transformation(Mianyang Central Hospital), School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, Ch…
  • Department of Otolaryngology- Head & Neck Surgery, West China Hospital of Sichuan University, Chengdu, China.

Förderung

  • the National Natural Sciences Foundation of China
  • Clinical Research Incubation Project of West China Hospital
  • Sichuan Provincial Science and Technology Department Key Research and Development Program
  • the National Key Research and Development Program of China
  • Sichuan Science and Technology Program
  • the Ministry of Education University-Industry Collaborative Education Program
  • Science and Technology Project of Sichuan Provincial Health Commission
  • the Achievement Transformation Fund of West China Hospital

Zitieren

APA

Jiang, Z., Yang, N., Jin, J., Zhang, Z., Lu, H., Xu, L., Chen, Y., Jin, L., Zhou, L., Yang, H., Liu, J., Zhang, W., Tong, A., & Peng, X. (2025). Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors. Journal for ImmunoTherapy of Cancer, 13(6), e011642. https://doi.org/10.1136/jitc-2025-011642

Vancouver

Jiang Z, Yang N, Jin J, Zhang Z, Lu H, Xu L, et al. Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors. Journal for ImmunoTherapy of Cancer. 2025;13(6):e011642. doi:10.1136/jitc-2025-011642

BibTeX
@article{Jiang2025,
  author = {Jiang, Zheng and Yang, Nian and Jin, Jing and Zhang, Zongliang and Lu, Huaqing and Xu, Long and Chen, Yongdong and Jin, Liyuan and Zhou, Liangxue and Yang, Hui and Liu, Jun and Zhang, Weiwei and Tong, Aiping and Peng, Xingchen},
  title = {Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {6},
  pages = {e011642},
  doi = {10.1136/jitc-2025-011642}
}
Kostenlos starten →